Related references
Note: Only part of the references are listed.Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases
Charu Singh et al.
JOURNAL OF NEUROSURGERY (2020)
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non -randomised, open -label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2020)
Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data
Eric J. Lehrer et al.
RADIOTHERAPY AND ONCOLOGY (2019)
Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors
Lizza E. L. Hendriks et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West et al.
LANCET ONCOLOGY (2019)
Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity
Giuseppe Minniti et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Effectiveness and safety of real concurrent stereotactic radiotherapy and immunotherapy in metastatic solid tumors: a systematic review
Salvatore Trapani et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
Linda Chen et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects
Kevin Diao et al.
JOURNAL OF NEUROSURGERY (2018)
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
Georgina V. Long et al.
LANCET ONCOLOGY (2018)
Intracerebral efficacy and tolerance of nivolumab in non small-cell lung cancer patients with brain metastases
Clement Gauvain et al.
LUNG CANCER (2018)
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
M. A. Socinski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Brain metastases treated with immune checkpoint inhibitors: A single center experience
Vidhya Karivedu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Access Programme (EAP) in Italy
P. Bidoli et al.
ANNALS OF ONCOLOGY (2017)
Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases
Kamran A. Ahmed et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Immune Checkpoint Inhibitors for Brain Metastases of Non-Small-Cell Lung Cancer
H. Ashinuma et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
A. M. Di Giacomo et al.
ANNALS OF ONCOLOGY (2015)
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Simon J. Dovedi et al.
CANCER RESEARCH (2014)
Radiologic and histologic consequences of radiosurgery for brain tumors
Ahmed Alomari et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
Chad Tang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
On the Merits and Limitations of Whole-Brain Radiation Therapy
Atif J. Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S. Peters et al.
ANNALS OF ONCOLOGY (2012)
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
Paul W. Sperduto et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Kim Margolin et al.
LANCET ONCOLOGY (2012)
Radiation as an immunological adjuvant: current evidence on dose and fractionation
Sandra Demaria et al.
FRONTIERS IN ONCOLOGY (2012)
Brain metastases: epidemiology and pathophysiology
IT Gavrilovic et al.
JOURNAL OF NEURO-ONCOLOGY (2005)
Share Paper
